FDA accepts safety data for canine longevity drugJanuary 13, 2026Loyal advances toward market approval with acceptance of Target Animal Safety section for its senior dog lifespan extension drug, LOY-002.
SPONSORED CONTENTKeep the Blaze at BaySee how an approach that manages the pain AND inflammation of canine OA can benefit your patients + Learn More
$45M additional funding bolsters development of canine longevity drugMarch 25, 2024The latest financing round brings the total funds raised for the first FDA-approved dog lifespan extension drug to $125M
Canine longevity drug starts clinical trialFebruary 1, 2024A whippet named Boo is the first dog dosed in the study to demonstrate healthy lifespan extension in dogs treated with LOY-002
